CRIS Current Research Information System

MALAGOLA, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.959
EU - Europa 1.533
AS - Asia 553
AF - Africa 124
SA - Sud America 5
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 1
Totale 4.178
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.956
GB - Regno Unito 480
SE - Svezia 298
DE - Germania 193
CN - Cina 189
IT - Italia 184
VN - Vietnam 154
SG - Singapore 99
UA - Ucraina 72
IE - Irlanda 70
IN - India 66
FR - Francia 60
RU - Federazione Russa 52
TG - Togo 52
ZA - Sudafrica 36
EE - Estonia 31
CH - Svizzera 24
CI - Costa d'Avorio 20
BG - Bulgaria 17
BE - Belgio 16
FI - Finlandia 13
JO - Giordania 13
IR - Iran 11
NG - Nigeria 8
JP - Giappone 7
SC - Seychelles 7
LB - Libano 5
BR - Brasile 3
EU - Europa 3
GR - Grecia 3
NL - Olanda 3
PT - Portogallo 3
RO - Romania 3
TR - Turchia 3
CA - Canada 2
ES - Italia 2
HK - Hong Kong 2
PL - Polonia 2
UZ - Uzbekistan 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AR - Argentina 1
BA - Bosnia-Erzegovina 1
CL - Cile 1
CZ - Repubblica Ceca 1
HU - Ungheria 1
KE - Kenya 1
LU - Lussemburgo 1
MK - Macedonia 1
MX - Messico 1
NZ - Nuova Zelanda 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 4.178
Salva come PNG Salva come JPEG
Città #
Southend 429
Fairfield 267
Chandler 201
Ashburn 172
Woodbridge 155
Dong Ket 154
Wilmington 121
Seattle 120
Houston 119
Ann Arbor 113
Cambridge 91
Princeton 87
Singapore 83
Dublin 69
Lomé 52
Nanjing 44
Jacksonville 42
Westminster 39
Padova 37
New York 36
Turin 31
Berlin 28
Bern 22
Saint Petersburg 22
Beijing 21
Bologna 21
Shenyang 21
Abidjan 20
Bremen 17
Florence 17
Sofia 17
Boardman 16
Hebei 15
Santa Clara 15
Amman 13
Brussels 13
Changsha 13
Helsinki 13
Jinan 11
Jiaxing 10
London 9
Medford 9
Milan 9
Nanchang 9
San Diego 9
Abeokuta 8
Haikou 7
Mülheim 7
Norwalk 7
Verona 7
Des Moines 6
Mahé 6
Tokyo 6
Olalla 5
Redmond 5
Bühl 4
Farra d'Isonzo 4
Leawood 4
Ningbo 4
Rome 4
Taizhou 4
Tianjin 4
Zanjan 4
Zhengzhou 4
Ancona 3
Falls Church 3
Guangzhou 3
Hangzhou 3
Louvain 3
Mountain View 3
Muizenberg 3
Paris 3
Plauen 3
Redwood City 3
Riva 3
Taiyuan 3
Washington 3
Andover 2
Brescia 2
Castel Guelfo di Bologna 2
Central District 2
Costa Mesa 2
Frankfurt am Main 2
Grafing 2
Hefei 2
Kilburn 2
Lanzhou 2
Las Vegas 2
Lausanne 2
Lisbon 2
Los Angeles 2
Martinengo 2
Montepulciano 2
Phoenix 2
Tappahannock 2
Toronto 2
Amsterdam 1
Artà 1
Athlone 1
Auckland 1
Totale 3.013
Salva come PNG Salva come JPEG
Nome #
Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia. 160
First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. 158
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 158
Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas 156
No preferential sensitivity of t(8;21) acute myeloid leukemias to cytosine arabinoside in vitro: is intensity of therapy or high dose Ara-C crucial for response? 152
Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia 150
Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation. 131
Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts 128
Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia 119
Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients. 119
Leukemia and multi-drug resistance: too many mechanisms of drug resistance or too many doctors resistant? 118
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 117
A new biomarker of response to 5-azacitidine therapy in MDS and AML patients: SIRPB1 116
Prompt resolution of nasal aspergillosis with intranasal instillation of liposomal amphotericin-B (amBisome) and granulocyte transfusions 115
Fludarabine, Cytarabine, Idarubicin and Etoposide (FLAIE) schedule is safe and active for young patients with newly diagnosed acute myeloid leukemia (AML): Results of a multicentric phase III Italian study 115
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 113
Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years 111
Molecular and cytogenetic characterization of a new case of t(5;17)(q35;q21) variant acute promyelocytic leukemia 110
Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target? 109
Consolidation therapy for adult acute myeloid leukemia: A systematic analysis according to evidence based medicine 107
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. 104
Resolving the diagnostic dilemma of T-cell clonal expansion after hematopoietic stem cell transplantation in T-cell lymphoma patients by TCR-gamma next generation sequencing 102
Bcr-Abl kinase domain mutations and resistance in Ph+ acute lymphoblastic leukemia from the imatinib to the 2nd-generation TKI era 100
Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives 98
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases 97
Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients 96
Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin 95
Kinetics of Th1/Th2 cytokines and lymphocyte subsets to predict chronic GVHD after allo-SCT: results of a prospective study. 93
Digital PCR (dPCR) Overcomes the Limitations in Detection and in Quantification of Quantitative PCR (qPCR) and Reveals Different Levels of BCR-ABL1 Copies/µl Among the Chronic Myeloid Leukemia (CML) Patients Achieving Major (MR3.0) or DEEP (MR4.0, MR4.5 and MR5.0) Molecular Response with Tyrosin Kynase Inhibitors (TKIs) 93
Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocation. 91
Molecular monitoring to identify a threshold of CBFbeta/MYH11 transcript below which continuous complete remission of acute myeloid leukemia inv16 is likely. 89
Mesenchymal stromal cells (MSCs) induce ex vivo proliferation and erythroid commitment of cord blood haematopoietic stem cells (CB-CD34+ cells) 85
Survival analysis of 409 consecutive patients with newly diagnosed acute myeloid leukemia treated with intensive induction therapy, with or without the addition of gemtuzomab-ozagomicin (GO) 85
INTERMITTENT IMATINIB (INTERIM) TREATMENT IN PH+-CML ELDERLY PATIENTS IN STABLE COMPLETE CYTOGENETIC RESPONSE 76
Soft tissue and skeletal involvement in FIP1L1-PDGFR-A positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission 75
The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients. 68
Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome. 67
Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly 65
Molecular monitoring of acute myeloid leukemia associated with inv(16): Threshold of CBFβ/MYH11 transcript copy number above which relapse occurs and below which continuous complete remission is likely (multiple letters) [8] 48
Managing chronic myeloid leukemia for treatment-free remission: A proposal from the GIMEMA CML WP 45
Two more inv(16) acute myeloid leukemia cases with infrequent CBFβ-MYH11 fusion transcript: Clinical and molecular findings [4] 22
PROSPECTIVE PHASE II STUDY ON LOW-DOSE 5-AZACYTIDINE FOR TREATMENT OF SYMPTOMATIC PATIENTS WITH LOW/INT-1 RISK MYELODISPLASIA 21
Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC 9
Totale 4.286
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.898
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.898
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020966 0 0 11 85 122 102 148 150 161 87 39 61
2020/2021596 112 46 10 25 11 24 8 38 49 32 29 212
2021/2022744 47 16 64 99 71 50 13 45 32 59 138 110
2022/2023954 113 149 39 125 57 67 29 53 162 14 109 37
2023/2024262 17 39 13 30 15 69 12 29 5 16 9 8
2024/2025145 19 114 12 0 0 0 0 0 0 0 0 0
Totale 4.286